HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

CB MECA

adenocine A3 receptor agonist

Also Known As:

CB-MECA; N(6)-(3-chlorobenzyl)-5'-N-methylcarboxamidoadenosine

Networked: 2 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Purines: 651
      - Purine Nucleosides: 360
        Adenosine: 12431
        CB MECA: 2
Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleosides: 6847
  - Purine Nucleosides: 360
    - Adenosine: 12431
      - CB MECA: 2
  - Ribonucleosides: 49
    - Adenosine: 12431
      - CB MECA: 2

Experts

1.	Ellery, C A: 1 article (10/2000)
2.	Knight, D R: 1 article (10/2000)
3.	MacAndrew, J T: 1 article (10/2000)
4.	Magee, W P: 1 article (10/2000)
5.	Oates, P J: 1 article (10/2000)
6.	Smith, A H: 1 article (10/2000)
7.	Tracey, W R: 1 article (10/2000)

Related Diseases

1.	Ischemia 10/01/1998 - "Five-min perfusion with CB-MECA before ischemia/reperfusion elicited a concentration-dependent reduction in infarct size (EC50: 0.3 nM). " 10/01/2000 - "This study investigated whether aldose reductase (AR) inhibition with zopolrestat, either alone or in combination with an adenosine A(3)-receptor agonist (CB-MECA), reduced myocardial ischemic injury in rabbit hearts subjected to 30 min of regional ischemia and 120 min of reperfusion. "
2.	Myocardial Ischemia (Ischemic Heart Diseases) 10/01/1998 - "The aim of this study was to characterize the adenosine A3 receptor agonist, N6-(3-chlorobenzyl)-5'-N-methylcarboxamidoadenosine (CB-MECA), evaluate its ability to reduce myocardial ischemia/reperfusion injury and determine the role of KATP-channel activation in A3 receptor-mediated cardioprotection. " 10/01/1998 - "Selective stimulation of adenosine A3 receptors with CB-MECA reduces myocardial ischemia/reperfusion injury via a mechanism which involves activation of KATP channels."
3.	Reperfusion Injury 10/01/1998 - "The aim of this study was to characterize the adenosine A3 receptor agonist, N6-(3-chlorobenzyl)-5'-N-methylcarboxamidoadenosine (CB-MECA), evaluate its ability to reduce myocardial ischemia/reperfusion injury and determine the role of KATP-channel activation in A3 receptor-mediated cardioprotection. " 10/01/1998 - "Selective stimulation of adenosine A3 receptors with CB-MECA reduces myocardial ischemia/reperfusion injury via a mechanism which involves activation of KATP channels."
4.	Infarction (Infarctions) 10/01/1998 - "Five-min perfusion with CB-MECA before ischemia/reperfusion elicited a concentration-dependent reduction in infarct size (EC50: 0.3 nM). " 10/01/2000 - "A modestly cardioprotective concentration of CB-MECA (0.2 nM) allowed a 50-fold reduction in zopolrestat concentration while providing a similar reduction in infarct size (infarct area/area at risk: control, 62 +/- 2%; 1 microM zopolrestat, 24 +/- 5%; 20 nM zopolrestat plus 0.2 nM CB-MECA, 20 +/- 4%). " 10/01/1998 - "The KATP channel inhibitors, glibenclamide and 5-HD, had no effect on control infarct size, yet significantly (P < 0.05) blunted the CB-MECA-dependent cardioprotection (glibenclamide: 49 +/- 6; 5-HD: 58 +/- 4% IA/AAR). "

Related Drugs and Biologics

1.	KATP Channels
2.	Adenosine A3 Receptor
3.	Aldehyde Reductase (Aldose Reductase)
4.	Adenosine (Adenocard)
5.	zopolrestat
6.	Glyburide (Glibenclamide)